The significant growth of Edwards Lifesciences over the past two decades, as highlighted by an 18.89% average annual return and outperforming the market, underscores the company's strong performance and potential for continued growth. This historical performance, coupled with a substantial market capitalization of $51.39 billion, suggests a positive outlook for EW's stock in the short term, especially for investors interested in long-term growth.